TLP
CYTK icon

Tri Locum Partners’s Cytokinetics CYTK Stock Holding History

Tri Locum Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5M Buy
+194,000
New +$13.9M 2.03% 16
2022
Q1 		– Sell
-33,379
Closed -$1.52M – 42
2021
Q4 		$1.52M Buy
+33,379
New +$1.29M 0.6% 28

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tri Locum Partners's CYTK Position: Q2 2026 in Review

Tri Locum Partners opened a new position in Cytokinetics (CYTK) in Q2 2026: 194,000 shares worth $16.5M. The stake represents 2.03% of the portfolio and ranks #16 among its holdings. This is a return to the name: Tri Locum Partners previously reported a position in CYTK as recently as Q4 2021.

Tri Locum Partners first reported a position in CYTK in Q4 2021 and has held it in 2 quarters since. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Tri Locum Partners held 194,000 shares of Cytokinetics worth $16.5M as of Q2 2026.
  • Cytokinetics was a new Tri Locum Partners position in Q2 2026.
  • Cytokinetics made up 2.03% of Tri Locum Partners's portfolio in Q2 2026, its #16 holding.
  • Tri Locum Partners first reported a position in Cytokinetics in Q4 2021 and has held it in 2 quarters since.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Tri Locum Partners's 13F filing for Q2 2026, filed 14 Aug 2026.